|Source||Humanized (from mouse)|
|(what is this?)|
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5. 
This drug was developed by Immunomedics, Inc.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab, American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|